[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351356-105":59,"doc-detail-351356-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","androgen-receptor-splice-variant-7-expression-levels-distinguish-ar-mutated-from-nonmutated-metastatic-castration-resistant-prostate-cancers-research-article","Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers - Research article","","New androgen receptor (AR) pathway inhibitors target ligand-dependent AR activation and can show activity in metastatic castration-resistant prostate cancer (mCRPC) resistant to established ARPIs, particularly in tumors with AR mutations. The study hypothesizes AR-mutated mCRPC has lower AR splice variant 7 (AR-V7) expression while remaining full-length AR (FL-AR) driven. Results show AR-mutated mCRPC biopsies with detectable AR mutations have significantly lower AR-V7 protein, better overall survival, and enhanced sensitivity to ARPIs, linked to splicing factor differences and independent of total splicing events.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/androgen-receptor-splice-variant-7-expression-levels-distinguish-ar-mutated-from-nonmutated-metastatic-castration-resistant-prostate-cancers-research-article/351356/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/androgen-receptor-splice-variant-7-expression-levels-distinguish-ar-mutated-from-nonmutated-metastatic-castration-resistant-prostate-cancers-research-article/351356.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What main relationship does the study propose between AR mutation status and AR-V7 expression?","Question",{"text":113,"@type":114},"AR-mutated mCRPC is proposed to exhibit lower AR splice variant 7 (AR-V7) expression while remaining driven by full-length AR (FL-AR).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do AR mutations relate to clinical outcomes and ARPI sensitivity in the study?",{"text":118,"@type":114},"Biopsies with detectable AR mutations show significantly lower AR-V7 protein levels, associate with better overall survival, and demonstrate enhanced sensitivity to ARPIs.",{"name":120,"@type":111,"acceptedAnswer":121},"Is the difference in AR-V7 linked to total splicing events?",{"text":122,"@type":114},"The study states the association is independent of differences in the total number of global splicing events, and may relate to splicing factor expression differences between AR-mutated and nonmutated mCRPC.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351356,1790167913,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nAndrogen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers  \nAlec Paschalis,1,2 Ines Figueiredo,1 Denisa Bogdan,1 Arian Lundberg,1 Rita Santos,1 Bora Gurel,1 Tarek Taha,1,2 Ossian Longoria,1,2 Ana Ferreira,1 Claudia Bertan,1 Nicholas Brittain,3 Ryan Nelson,3 Laura Walker,3 Antje Neeb,1 Jonathan Welti,1 Wei Yuan,1 Costas Mitsopoulos,1 Stephen R. Plymate,4 Michael C. Haffner,5,6 Adam G. Sowalsky,7 Suzanne Carreira,1 Adam Sharp,1,2 Luke Gaughan,3 and Johann de Bono1,2  \n1The Institute of Cancer Research, London, United Kingdom. 2The Royal Marsden Hospital, London, United Kingdom. 3Newcastle University Centre for Cancer, United Kingdom. 4Department of Medicine, University of Washington School of Medicine and VAPSHCS-GRECC, Seattle, Washington, USA. 5Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA. 6Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA. 7Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA.  \nNew androgen receptor (AR) pathway inhibitors (ARPIs) in clinical development, including AR degraders and CYP11A inhibitors, largely target ligand-dependent AR activation and have reported antitumor activity in metastatic castration-resistant prostate cancer (mCRPC) resistant to established ARPIs, predominately against tumors with AR mutations. We hypothesized that ARmutated mCRPC exhibits lower AR splice variant 7 (AR-V7) expression and remains full-length–AR (FL-AR) driven, explaining, in part, the antitumor activity of these AR ligand–binding domain (LBD) targeting drugs. The data herein demonstrate that mCRPC tissue biopsies with detectable AR mutations express significantly lower levels ofAR-V7 protein and associate with better overall survival and enhanced sensitivity toARPIs. This is independent of differences in the total number of global splicing events but may be related to differences in splicing factor expression between AR-mutated and nonmutated mCRPC. In conclusion, ARmutated mCRPC frequently exhibits low AR-V7 expression, arguably explaining the enhanced sensitivity toARPIs observed in these cancers. Consequently, AR mutation status may serve as a biomarker to predict response to AR-directed therapies.  \nIntroduction  \nProstate cancer (PC) is one of the most common cancers in men and is a leading cause of male cancer death globally. Deregulated androgen receptor (AR) signaling is a key driver of PC development and progression and remains a major therapeutic target in advanced disease, with AR pathway inhibitors (ARPIs) having improved clinical outcomes from PC (1, 2) . However, all advanced  \nPCs eventually become resistant to ARPIs, such as abiraterone, enzalutamide, apalutamide, and darolutamide, leading to fatal disease progression. Resistance to ARPIs can develop due to the emergence of constitutively active alternatively spliced variants of the AR (AR-Vs) that lack the regulatory AR ligand-binding domain (LBD), which is the target of currently approved and new ARPIs in clinical development, including AR degraders and CYP11A  \nAuthorship note: AP, IF, DB, and AL are co–first authors.  \nConflict of interest: AP, AL, DB, JW, WY, IF, BG, TT, OL, KM, SC, AS, and JdB are all employees of The Institute of Cancer Research (ICR), which has a commercial interest inabiraterone, PARP inhibition in DNA repair–defective cancers, and PI3K/AKT pathway inhibitors (no personal income) . The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. AP has been the CI/PI of industry-sponsored clinical trials and has received honoraria from Boehringer Ingelheim. MCH served as a paid consultant/received honoraria from Pfizer and has received research funding from Merck, Novart","cbCaikDZ9K7JN4Qi","https://ap.wps.com/l/cbCaikDZ9K7JN4Qi","pdf",10974775,"English","# Introduction\n## Prostate cancer and AR pathway inhibitors\n## Mechanisms of resistance and role of AR splice variants\n# Results and conclusions\n## AR-V7 expression in AR-mutated mCRPC\n## Clinical associations with survival and ARPI sensitivity","[{\"question\":\"What main relationship does the study propose between AR mutation status and AR-V7 expression?\",\"answer\":\"AR-mutated mCRPC is proposed to exhibit lower AR splice variant 7 (AR-V7) expression while remaining driven by full-length AR (FL-AR).\"},{\"question\":\"How do AR mutations relate to clinical outcomes and ARPI sensitivity in the study?\",\"answer\":\"Biopsies with detectable AR mutations show significantly lower AR-V7 protein levels, associate with better overall survival, and demonstrate enhanced sensitivity to ARPIs.\"},{\"question\":\"Is the difference in AR-V7 linked to total splicing events?\",\"answer\":\"The study states the association is independent of differences in the total number of global splicing events, and may relate to splicing factor expression differences between AR-mutated and nonmutated mCRPC.\"}]","Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers - Research article | PDF",1790093706,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9d90f2c055c54ac00c124b8ba5fa462.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93700371ba536572182aa79436924b1e.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/511faf8f78a884528337473457e804d5.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6c36722ff93663ba2e0916ca77824d2.webp",980,1311]